Edmp Inc. Has $4.27 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Edmp Inc. reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,399 shares of the medical research company’s stock after selling 370 shares during the quarter. Amgen comprises about 4.1% of Edmp Inc.’s investment portfolio, making the stock its 7th largest holding. Edmp Inc.’s holdings in Amgen were worth $4,274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter worth approximately $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $36,000. Wingate Wealth Advisors Inc. bought a new stake in Amgen during the fourth quarter worth approximately $52,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen in the third quarter worth approximately $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.4 %

Shares of AMGN stock opened at $294.79 on Tuesday. The company has a market capitalization of $158.46 billion, a price-to-earnings ratio of 39.05, a PEG ratio of 3.01 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26. The stock’s 50 day simple moving average is $272.26 and its 200 day simple moving average is $302.77. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, research analysts predict that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.23%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 119.21%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMGN. Deutsche Bank Aktiengesellschaft cut their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Bank of America upped their price target on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research report on Thursday, February 6th. Finally, William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.